InjectionClinical Overview
Piperacillin and Tazobactam is an extended-spectrum ureidopenicillin combined with a beta-lactamase inhibitor. Piperacillin exhibits potent bactericidal activity against Pseudomonas aeruginosa, Enterobacteriaceae, and anaerobes by inhibiting cell wall synthesis, while tazobactam inactivates plasmid- and chromosomally-mediated beta-lactamases. Indicated for nosocomial and severe community-acquired pneumonia, complicated intra-abdominal infections, complicated skin/soft tissue infections, febrile neutropenia, and complicated urinary tract infections.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered strictly by slow intravenous infusion over 30 minutes (or extended infusion over 3-4 hours in ICU protocols) by qualified hospital clinicians after reconstitution with 0.9% Normal Saline or 5% Dextrose. Incompatible with aminoglycosides in the same infusion line.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea, nausea, headache, insomnia, constipation, and rash. Rare/Severe: Acute kidney injury (especially when co-administered with vancomycin), severe anaphylaxis, Clostridioides difficile colitis, leukopenia, and bleeding tendencies due to platelet dysfunction.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients with severe allergy to penicillins, cephalosporins, or beta-lactamase inhibitors. Requires strict dose adjustments in renal impairment. Monitor renal function, serum potassium, and CBC closely in critically ill patients.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Ceftazidime 250mg + Tazobactum 31.25mg Injection
Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.
Ceftazidime 1000 mg + Tazobactum 125 mg Injection
Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.